This disclosure relates to infusion pump assemblies and, more particularly, to infusion pump assemblies that include multiple microprocessors.
An infusion pump assembly may be used to infuse a fluid (e.g., a medication or nutrient) into a user. The fluid may be infused intravenously (i.e., into a vein), subcutaneously (i.e., into the skin), arterially (i.e., into an artery), and epidurally (i.e., into the epidural space).
Infusion pump assemblies may administer fluids in ways that would be impractically expensive/unreliable if performed manually by nursing staff. For example, an infusion pump assembly may repeatedly administer small quantities of an infusible fluid (e.g., 0.1 mL per hour), while allowing the user to request one-time larger “bolus” doses.
Unfortunately, the failure of a microprocessor included within a single-processor infusion pump assembly may result in the infusion pump assembly ceasing to operate. Additionally, in an infusion pump assembly that includes multiple microprocessors executing code written in a common language, an undisclosed problem within the common-language code may compromise the operation of all microprocessors included within the multi-processor infusion pump assembly.
In a first implementation, an infusion pump assembly includes a reservoir assembly configured to contain an infusible fluid. A motor assembly is configured to act upon the reservoir assembly and dispense at least a portion of the infusible fluid contained within the reservoir assembly. Processing logic is configured to provide one or more control signals to the motor assembly. The one or more control signals are processable by the motor assembly to effectuate the dispensing of the at least a portion of the infusible fluid contained within the reservoir assembly. The processing logic includes a primary microprocessor configured to execute one or more primary applications written in a first computer language; and a safety microprocessor configured to execute one or more safety applications written in a second computer language.
One or more of the following features may be included. A primary power supply may be configured to provide primary electrical energy to at least a portion of the processing logic. A backup power supply may be configured to provide backup electrical energy to the at least a portion of the processing logic in the event that the primary power supply fails to provide the primary electrical energy to the at least a portion of the processing logic. The primary power supply may be a first battery; and the backup power supply may be a super capacitor assembly.
The processing logic may include one or more circuit partitioning components configured to divide the processing logic into primary processing logic and backup processing logic. The primary processing logic may include the primary microprocessor. The backup processing logic may include the safety microprocessor.
The one or more circuit partitioning components may include one or more of a diode assembly and a current limiting assembly. The diode assembly may be configured to allow the primary power supply to charge the backup power supply while prohibiting the backup power supply from providing backup electrical energy to the primary processing logic in the event that the primary power supply fails to provide the primary electrical energy to the primary processing logic.
The one or more primary applications written in the first computer language may be chosen from the group consisting of an operating system, an executive loop and a software application. The one or more safety applications written in the second computer language may be chosen from the group consisting of an operating system, an executive loop and a software application.
The primary power supply may be configured to provide electrical energy to one or more subsystems included within the infusion pump assembly. The primary power supply and the backup power supply may be configured to provide electrical energy to an audio system included within the infusion pump assembly. The audio system may be configured to provide an escalating alarm sequence in the event of a loss of a beacon signal, wherein the escalating alarm sequence includes at least a low-intensity alarm and a high-intensity alarm.
The first computer language may be chosen from the group consisting of Ada, Basic, Cobol, C, C++, C#, Fortran, Visual Assembler, Visual Basic, Visual J++, Java, and Java Script. The second computer language may be chosen from the group consisting of Ada, Basic, Cobol, C, C++, C#, Fortran, Visual Assembler, Visual Basic, Visual J++, Java, and Java Script.
In another implementation, an infusion pump assembly includes a reservoir assembly configured to contain an infusible fluid. A motor assembly is configured to act upon the reservoir assembly and dispense at least a portion of the infusible fluid contained within the reservoir assembly. Processing logic is configured to provide one or more control signals to the motor assembly. The one or more control signals are processable by the motor assembly to effectuate the dispensing of the at least a portion of the infusible fluid contained within the reservoir assembly. The processing logic includes one or more circuit partitioning components configured to divide the processing logic into primary processing logic and backup processing logic. A primary microprocessor is included within the primary processing logic and configured to execute one or more primary applications written in a first computer language. A safety microprocessor is included within the backup processing logic and configured to execute one or more safety applications written in a second computer language.
One or more of the following features may be included. The one or more primary applications written in the first computer language may be chosen from the group consisting of an operating system, an executive loop and a software application. The one or more safety applications written in the second computer language may be chosen from the group consisting of an operating system, an executive loop and a software application. A primary power supply may be configured to provide primary electrical energy to at least a portion of the processing logic. A backup power supply may be configured to provide backup electrical energy to the at least a portion of the processing logic in the event that the primary power supply fails to provide the primary electrical energy to the at least a portion of the processing logic.
The first computer language may be chosen from the group consisting of Ada, Basic, Cobol, C, C++, C#, Fortran, Visual Assembler, Visual Basic, Visual J++, Java, and Java Script. The second computer language may be chosen from the group consisting of Ada, Basic, Cobol, C, C++, C#, Fortran, Visual Assembler, Visual Basic, Visual J++, Java, and Java Script.
In another implementation, a computer program product resides on a computer readable medium having a plurality of instructions stored on it. When executed by a processor, the instructions cause the processor to perform operations including receiving, on a first microprocessor executing one or more applications written in a first computer language, an initial command processable by the one or more applications written in the first computer language. The initial command is converted into a modified command processable by one or more applications written in a second computer language. The modified command is provided to a second microprocessor executing the one or more applications written in the second computer language.
One or more of the following features may be included. The one or more applications written in the first computer language may be chosen from the group consisting of an operating system, an executive loop and a software application. The one or more applications written in the second computer language may be chosen from the group consisting of an operating system, an executive loop and a software application.
The first microprocessor may be a primary microprocessor. The one or more applications written in the first computer language may be one or more primary applications. The second microprocessor may be a safety microprocessor. The one or more applications written in the second computer language may be one or more safety applications.
The first computer language may be chosen from the group consisting of Ada, Basic, Cobol, C, C++, C#, Fortran, Visual Assembler, Visual Basic, Visual J++, Java, and Java Script. The second computer language may be chosen from the group consisting of Ada, Basic, Cobol, C, C++, C#, Fortran, Visual Assembler, Visual Basic, Visual J++, Java, and Java Script.
The details of one or more implementations are set forth in the accompanying drawings and the description below. Other features and advantages will become apparent from the description, the drawings, and the claims.
Like reference symbols in the various drawings indicate like elements.
Referring to
Infusion pump assembly 10 may include processing logic 16 that executes one or more processes that may be required for infusion pump assembly 10 to operate properly. Processing logic 16 may include one or more microprocessors (to be discussed below in greater detail), one or more input/output controllers (not shown), and cache memory devices (not shown). One or more data buses and/or memory buses may be used to interconnect processing logic 16 with one or more subsystems.
Examples of such subsystems may include but are not limited to memory system 20, input system 22, display system 24, vibration system 26, audio system 28, motor assembly 30, force sensor 32, and displacement detection device 34. Infusion pump assembly 10 may include primary power supply 36 (e.g. a first battery) for providing electrical power to at least a portion of processing logic 16 and one or more of the subsystems (e.g., memory system 20, input system 22, display system 24, vibration system 26, audio system 28, motor assembly 30, force sensor 32, and displacement detection device 34).
Infusion pump assembly 10 may include reservoir assembly 38 configured to contain infusible fluid 12. In some embodiments, the reservoir assembly 38 may be a reservoir assembly similar to that described in U.S. Patent Application Publication No. US-2004-0135078-A1, published Jul. 15, 2004, which is herein incorporated by reference in its entirety. In other embodiments, the reservoir assembly may be any assembly in which fluid may be acted upon such that at least a portion of the fluid may flow out of the reservoir assembly, for example, the reservoir assembly, in various embodiments, may include but is not limited to: a barrel with a plunger, a cassette or a container at least partially constructed of a flexible membrane.
Plunger assembly 40 may be configured to displace infusible fluid 12 from reservoir assembly 38 through cannula assembly 42 so that infusible fluid 12 may be delivered to user 14. In this particular embodiment, plunger assembly 40 is shown to be displaceable by partial nut assembly 44, which may engage lead screw assembly 46 that may be rotatable by motor assembly 30 in response to signals received from processing logic 16. In this particular embodiment, the combination of motor assembly 30, plunger assembly 40, partial nut assembly 44, and lead screw assembly 46 may form a pump assembly that effectuates the dispensing of infusible fluid 12 contained within reservoir assembly 38. An example of partial nut assembly 44 may include but is not limited to a nut assembly that is configured to wrap around lead screw assembly 46 by e.g., 30 degrees. In some embodiments, the pump assembly may be similar to one described in U.S. Pat. No. 7,306,578, issued Dec. 11, 2007, which is herein incorporated by reference in its entirety.
During operation of infusion pump assembly 10, infusible fluid 12 may be delivered to user 14 in accordance with e.g. a defined delivery schedule. For illustrative purposes only, assume that infusion pump assembly 10 is configured to provide 0.00025 mL of infusible fluid 12 to user 14 every three minutes. Accordingly, every three minutes, processing logic 16 may provide the power to motor assembly 30 to allow motor assembly 30 to rotate lead screw assembly 46 the appropriate amount so that partial nut assembly 44 (and therefore plunger assembly 40) may be displaced the appropriate amount in the direction of arrow 48 so that 0.00025 mL of infusible fluid 12 are provided to user 14 (via cannula 42). It should be understood that the volume of infusible fluid 12 that may be provided to user 14 may vary based upon, at least in part, the nature of the infusible fluid (e.g., the type of fluid, concentration, etc.), use parameters (e.g., treatment type, dosage, etc.), as well as various other factors that will be understood by one having skill in the art. As such, the foregoing illustrative example should not be construed as a limitation of the present disclosure.
Force sensor 32 may be configured to provide processing logic 16 with data concerning the force required to drive plunger assembly 40 into reservoir assembly 38. Force sensor 32 may include one or more strain gauges and/or pressure sensing gauges and may be positioned between motor assembly 30 and an immovable object (e.g. bracket assembly 50) included within infusion pump assembly 10.
In one embodiment, force sensor 32 includes four strain gauges (not shown), such that: two of the four strain gauges are configured to be compressed when driving plunger 40 into reservoir assembly 38; and two of the four strain gauges are configured to be stretched when driving plunger 40 into reservoir assembly 38. The four strain gauges (not shown) may be connected to a Wheatstone Bridge (not shown) that produces an analog force signal (not shown) that is a function of the pressure sensed by force sensor 32. The analog force signal (not shown) produced by force sensor 32 may be provided to an analog-to-digital converter (not shown) that may convert the analog force signal (not shown) into a digital force signal (not shown) that may be provided to processing logic 16. An amplifier assembly (not shown) may be positioned prior to the above-described analog-to-digital converter and may be configured to amplify the output of e.g., force sensor 32 to a level sufficient to be processed by the above-described analog-to-digital converter.
Motor assembly 30 may be configured as e.g., a brush-type DC electric motor. Further, motor assembly 30 may include a reduction gear assembly (not shown) that e.g. requires motor assembly 30 to rotate e.g., three-thousand revolutions for each revolution of lead screw assembly 46, thus increasing the torque and resolution of motor assembly 30 by a factor of three-thousand.
Referring also to
Diode assembly 100 may be configured to allow primary power supply 36 to charge backup power supply 108 included within backup processing logic 106, while prohibiting backup power supply 108 from providing backup electrical energy 110 to primary processing logic 104 in the event that some form of failure prevents primary electrical energy 112 from providing primary processing logic 104. An example of backup power supply 108 may include but is not limited to a super capacitor assembly. An example of such a super capacitor assembly may include but is not limited to an electric double-layer capacitor manufactured by Elna Co. Ltd. of Yokohama, Japan.
Current limiting assembly 102 may be configured to limit the amount of primary electrical energy 112 available to charge backup power supply 108. Specifically, as primary power supply 36 may be configured to charge backup power supply 108, the amount of current available from primary power supply 36 may be limited to e.g., avoid depriving primary processing logic 104 of a requisite portion of primary electrical energy 112.
Primary processing logic 104 may include primary microprocessor 114 and voltage booster circuit 116. An example of primary microprocessor 114 may include but is not limited to a H8S/2000 manufactured by Renesas Technology America Inc. of San Jose, Calif. Voltage booster circuit 116 may be configured to increase the voltage potential of primary electrical energy 112 provided by primary power supply 36 to a level sufficient to power primary microprocessor 114. An example of voltage booster circuit 116 may include but is not limited to a LTC3421 manufactured by Linear Technology of Milpitas, Calif.
Current limiting assembly 102 may be configured to limit the amount of current available to charge backup power supply 108 during the power-up of primary microprocessor 114. Specifically and for illustrative purposes, current limiter assembly 102 may be controlled by primary microprocessor 114 and current limiting assembly 102 may be disabled (i.e., provide no charging current to backup power supply 108) until after primary microprocessor 114 is fully powered up. Upon primary microprocessor 114 being fully powered up, primary microprocessor 114 may now enable current limiting assembly 102, thus providing charging current to backup power supply 108. Alternatively and upon being initially energized, current limiting assembly 102 may be configured to prohibit the flow of charging current to backup power supply 108 for a time sufficient to allow for the powering up of primary microprocessor 114.
Backup processing logic 106 may include backup power supply 108 and safety microprocessor 118. An example of safety microprocessor 118 may include but is not limited to a MSP430 manufactured by Texas Instruments of Dallas, Tex.
Primary power supply 36 may be configured to provide primary electrical energy 112 to at least a portion of processing logic 16. Specifically and during normal operation of infusion pump assembly 10, primary power supply 36 may be configured to provide primary electrical energy 112 to all of processing logic 16 (including the various components of primary processing logic 104 and backup processing logic 106), as well as various subsystems included within infusion pump assembly 10.
Examples of such subsystems may include but are not limited to memory system 20, input system 22, display system 24, vibration system 26, audio system 28, motor assembly 30, force sensor 32, and displacement detection device 34.
Backup power supply 108 may be configured to provide backup electrical energy 110 to the at least a portion of processing logic 16 in the event that primary power supply 36 fails to provide primary electrical energy 112 to at least a portion of processing logic 16. Specifically, in the event that primary power supply 36 fails and, therefore, can no longer provide primary electrical energy 112 to processing logic 16, backup power supply 108 may be configured to provide backup electrical energy 110 to backup processing logic 106.
For illustrative purposes only, assume that infusion pump assembly 10 is operating normally and primary power supply 36 is providing primary electrical energy 112 to processing logic 16. As discussed above, voltage booster circuit 116 may increase the voltage potential of primary electrical energy 112 to a level sufficient to power primary microprocessor 114, wherein voltage booster circuit 116 and primary microprocessor 114 are both included within primary processing logic 104.
Further, diode assembly 100 may allow a portion of primary electrical energy 112 to enter backup processing logic 106, thus enabling the operation of safety microprocessor 118 and the charging of backup power supply 108. As discussed above an example of backup power supply 108 may include but is not limited to a super capacitor. As discussed above, current limiter assembly 102 may limit the quantity of current provided by primary power supply 36 to backup processing logic 106, thus preventing the diversion of too large a portion of primary electrical energy 112 from primary processing logic 104 to backup processing logic 106.
Accordingly, in addition to powering safety microprocessor 118, primary power supply 36 may charge backup power supply 108. In a preferred embodiment, backup power supply 108 is a 0.33 farad super capacitor.
Safety microprocessor 118 may monitor the status of primary power supply 36 by monitoring the voltage potential present at the input of voltage booster circuit 116. Alternatively, safety microprocessor 118 may monitor the status of primary power supply 36 by e.g. monitoring (via conductor 124) the voltage potential present at the output of voltage booster circuit 116. Alternatively, safety microprocessor 118 may monitor the status of primary power supply 36 by monitoring the voltage potential present at the input of voltage booster circuit 116. Further still, safety microprocessor 118 and primary microprocessor 114 may be electrically-coupled via e.g. conductor 126 and primary microprocessor 114 may be configured to continuously provide a “beacon” signal to safety microprocessor 118. Conductor 126 may include isolation circuit 128 (e.g., one or more diodes assemblies) to electrically isolate safety microprocessor 118 and primary microprocessor 114. Accordingly, provided safety microprocessor 118 continues to receive the “beacon” signal from primary microprocessor 114, primary microprocessor 114 is functioning and, therefore, being properly powered by primary power supply 36. In the event that safety microprocessor 118 fails to receive the “beacon” signal from primary microprocessor 114, an alarm sequence may be initiated.
Further still, safety microprocessor 118 may be configured to continuously provide a “beacon” signal to primary microprocessor 114. Accordingly, provided primary microprocessor 114 continues to receive the “beacon” signal from safety microprocessor 118, safety microprocessor 118 is functioning and, therefore, being properly powered by backup power supply 108. In the event that primary microprocessor 114 fails to receive the “beacon” signal from safety microprocessor 118, an alarm sequence may be initiated.
As used in this disclosure, a “beacon” signal may be considered an event that is performed by primary microprocessor 114 (and/or safety microprocessor 118) solely for the purpose of making the presence of primary microprocessor 114 (and/or safety microprocessor 118) known. Additionally/alternatively, the “beacon” signal may be considered an event that is performed by primary microprocessor 114 (and/or safety microprocessor 118) for the purpose of performing a task, wherein the execution of this event is monitored by safety microprocessor 118 (and/or primary microprocessor 114) to confirm the presence of primary microprocessor 114 (and/or safety microprocessor 118).
Assume for illustrative purposes that primary power supply 36 fails. For example, assume that primary power supply 36 physically fails (as opposed to simply becoming discharged). Examples of such a failure may include but are not limited to the failing of a cell (not shown) within primary power supply 36 and the failing of a conductor (e.g., one or more of conductors 120, 122) that electrically-couples primary power supply 36 to processing logic 16. Accordingly, in the event of such a failure, primary power supply 36 may no longer provide primary electrical energy 112 to processing logic 16.
However, when such a failure of primary power supply 36 occurs, the voltage potential present at the output of voltage booster circuit 116 and the voltage potential present at the input of voltage booster circuit 116 may be reduced to zero. Since safety microprocessor 118 may monitor (as discussed above) one or more of these voltage potentials, safety microprocessor 118 may be knowledgeable that primary power supply 36 has failed.
Further, when such a failure of primary power supply 36 occurs, primary microprocessor 114 will no longer be powered and, therefore, primary microprocessor 1141 will no longer produce the above-described “beacon” signals. Since safety microprocessor 118 monitors the above-described “beacon” signals, safety microprocessor 118 may be knowledgeable that primary power supply 36 has failed.
As discussed above, in the event of such a failure of primary power supply 36, as diode assembly 100 is reversed-biased, backup power supply 108 may not provide backup electrical energy 110 to primary processing logic 104. Accordingly, primary processing logic 104 will know longer function.
Upon sensing the failure of primary power supply 36, safety microprocessor 118 may initiate an alarm sequence that may result in audio system 28 being energized. Audio system 28 may be controllable by both safety microprocessor 118 and primary microprocessor 114. Alternatively, a separate audio system may be used for each of safety microprocessor 118 and primary microprocessor 114. An example of audio system 118 may include but is not limited to a Piezo electric diaphragm, an example of which may include but is not limited to a 7BB-15-6 manufactured by Murata of Kyoto, Japan.
Audio system 28 may further include an RS232 line driver circuit 54, such as a MAX3319/MAX3221 manufactured by Maxim Integrated Products of Sunnyvale, Calif. One or more of primary microprocessor 114 and safety microprocessor 118 may be configured to provide an alarm control signal (e.g., a square wave; not shown) to RS232 line driver circuit 52 to generate an alarm output signal (not shown) that may be provided to and may drive the above-described Piezo electric diaphragm.
The alarm sequence initiated by safety microprocessor 118 is intended to inform user 14 of the failure of primary power supply 36 so that user 14 may take the appropriate action (e.g. seeking an alterative means to have their therapy performed and/or having infusion pump assembly 10 repaired/replaced). Backup power supply 108 may be sized so that safety microprocessor 118 and audio system 28 may continue to function for up to fifteen minutes or more after the failure of primary power supply 36 (i.e., depending on design specifications).
The alarm sequence initiated by safety microprocessor 118 and/or primary microprocessor 114 may be an “escalating” alarm sequence in some embodiments. For example, at first a discrete “vibrating” alarm may be initiated (via vibration system 26). In the event that this “vibrating” alarm is not acknowledged within a defined period of time (e.g., one minute), a low volume audible alarm may be initiated. In the event that this low volume alarm is not acknowledged within a defined period of time (e.g., one minute), a medium volume audible alarm may be initiated. In the event that this medium volume alarm is not acknowledged within a defined period of time (e.g., one minute), a high volume audible alarm may be initiated. The escalating alarm sequence may provide a notification to user 14, in which the notification may be discrete or less disruptive at the onset. The initially discrete or less disruptive notification may be advantageous as user 14 may experience minimal disruption. However, in the event that user 14 does not acknowledge the alarm, the escalating nature of the alarm may provide for additional layers of safety to user 14. Additionally, in a case of audio system 28 error, or vibration system 26 error, the escalating alarm sequence, which may include both vibration and audio alarms, may insure that user 14 may be notified regardless of whether both systems 26, 28 are functioning.
Audio system 28, in some embodiments, may be configured to perform a self test upon power up. For example, upon infusion pump assembly 10 being initially powered up, audio system 28 may provide a “beep-type” signal to each sound generating device included within audio system 28. In the event that user 14 does not hear these “beep-type” signal(s), user 14 may take the appropriate action (e.g. seeking an alterative means to have their therapy performed and/or having infusion pump assembly 10 repaired/replaced). As discussed above, audio system 28 may be controllable by safety microprocessor 118 and/or primary micro-processor 114. Accordingly, when performing the above-described self test upon power up, safety microprocessor 118 and/or primary microprocessor 114 may control the above-described self test. This feature may provide for additional safety to user 14, as user 14 may be alerted to a system error earlier than may otherwise be the case. Thus, a method may be provided to notify the user early of system errors. Also, the system may otherwise not be aware of an error in audio system 28, thus, this feature provides for identification of a failure by user 14 that may otherwise go undetected.
During the failure of primary power supply 36, safety microprocessor 118 may continue to monitor the voltage potential present at the output of voltage booster circuit 116 and/or the voltage potential present at the input of voltage booster circuit 116. Additionally, safety microprocessor 118 may continue to monitor for the presence of the above-described “beacon” signals. Accordingly, in the event that the failure of primary power supply 36 was a temporary event (e.g. primary power supply 36 is an out-of-date battery and is being replaced with a new battery), safety microprocessor 118 may be knowledgeable when primary power supply 36 is once again functioning properly.
Upon primary power supply 36 once again functioning properly, diode assembly 100 and current limiting assembly 102 may allow a portion of primary electrical energy 112 produced by primary power supply 36 to recharge backup power supply 108.
Additionally, safety microprocessor 118 and primary microprocessor 114 may each maintain a real-time clock, so that the various doses of infusible fluid may be dispensed at the appropriate time of day. As primary microprocessor 114 was not functioning during the failure of primary power supply 36, the real-time clock maintained within primary microprocessor 114 may no longer be accurate. Accordingly, the real-time clock maintained within safety microprocessor 118 may be used to reset the real-time clock maintained within primary microprocessor 114.
In order to further enhance the reliability and safety of infusion pump assembly 10, primary microprocessor 114 and safety microprocessor 118 may each execute applications written in different programming languages. For example, primary microprocessor 114 may be configured to execute one or more primary applications written in a first computer language, while safety microprocessor 118 may be configured to execute one or more safety applications written in a second computer language.
Examples of the first computer language in which the primary applications are written may include but are not limited to Ada, Basic, Cobol, C, C++, C#, Fortran, Visual Assembler, Visual Basic, Visual J++, Java, and Java Script languages. In a preferred embodiment, the first computer language in which the primary applications (executed on primary microprocessor 114 ) are written is the C++ computer language.
Examples of the second computer language in which the safety applications are written may include but are not limited to Ada, Basic, Cobol, C, C++, C#, Fortran, Visual Assembler, Visual Basic, Visual J++, Java, and Java Script languages. In a preferred embodiment, the second computer language in which the safety applications (executed on safety microprocessor 118) are written is the C computer language.
Further, assuming that primary microprocessor 114 and safety microprocessor 118 are different types of microprocessors and, therefore, use different compilers; the compiled code associated with the primary applications executed by primary microprocessor 114 and the safety applications executed on safety microprocessor 118 may be different (regardless of the whether the primary applications and the safety applications were written in the same computer language.
Examples of the one or more primary applications written in the first computer language and executable on primary microprocessor 114 may include but are not limited to an operating system (e.g., Linux™, Unix™, Windows CE™), an executive loop and various software applications. Further, examples of the one or more safety applications written in the second computer language and executable on safety microprocessor 118 may include but are not limited to an operating system (e.g., Linux™, Unix™, Windows CE™), an executive loop and various software applications.
Accordingly, primary processing logic 104 and backup processing logic 106 may each be configured as a separate stand-alone autonomous computing device. Therefore, primary microprocessor 114 included within primary processing logic 104 may execute a first operating system (e.g. Linux™) and safety microprocessor 118 included within backup processing logic 106 may execute an executive loop.
Additionally, primary microprocessor 114 included within primary processing logic 104 may execute one or more software applications (e.g. graphical user interface applications, scheduling applications, control applications, telemetry applications) executable within (in this example) a Linux™ operating system. Further, safety microprocessor 118 included within backup processing logic 106 may execute one or more software applications (e.g. graphical user interface applications, scheduling applications, control applications, telemetry applications) executable within (in this example) the executive loop.
By utilizing diverse computer languages and/or diverse operating systems, infusion pump assembly may be less susceptible to e.g. computer-language bugs, operating-system bugs, and/or computer viruses.
One or more of primary microprocessor 114 (included within primary processing logic 104 of processing logic 16) and safety microprocessor 118 (included within backup processing logic 106 of processing logic 16) may execute confirmation process 52 (
The instruction sets and subroutines of confirmation process 52, which may be stored on a storage device (e.g., memory system 20) accessible by processing logic 16, may be executed by one or more processors (e.g., primary microprocessor 114 and/or safety microprocessor 118) and one or more memory architectures (e.g., memory system 20) included within infusion pump assembly 10. Examples of memory system 20 may include but are not limited to: a random access memory; a read-only memory; and a flash memory.
Referring also to
As discussed above, safety microprocessor 118 (included within backup processing logic 106) may be executing the executive loop. Accordingly, command 130 may not be provided to safety microprocessor 118 in its native form, as safety microprocessor 118 may not be capable of processing command 130, due to safety microprocessor 118 executing the executive loop and primary microprocessor 114 executing the Linux™ operating system.
Accordingly, confirmation process 52 may convert 152 initial command 130 into a modified command (e.g., command 132) that may be processable by e.g., safety microprocessor 118 (included within backup processing logic 106) that may be executing the executive loop. For example, confirmation process 52 may convert 152 initial command 130 into modified command 132 that is transmittable via a communication protocol (not shown) that effectuates the communication of primary microprocessor 114 and safety microprocessor 118. Once command 130 is converted 152 into modified command 132, modified command 132 may be provided 154 to e.g., safety microprocessor 118 (included within backup processing logic 106) that may be executing e.g., the executive loop.
Once received by e.g., safety microprocessor 118 (included within backup processing logic 106), safety microprocessor 118 may process modified command 132 and provide (via e.g., display system 24) a visual confirmation to user 14. Prior to processing modified command 132, confirmation process 52 may convert modified command 132 into a native command (not shown) processable by safety microprocessor 118. For example, upon receiving modified command 132, safety microprocessor 118 may process received modified command 132 to render (on display system 24) a visual confirmation.
Upon processing modified command 132, confirmation process 52 may render on display system 24 a message that states “Dispense 0.50 U Dose?”. Upon reading this message, user 14 may either authorize the dispensing of the 0.50 mL dose or cancel the dispensing of the 0.50 mL dose. Accordingly, if user 14 authorizes the dispensing of the 0.50 mL dose of infusible fluid 12, the accuracy of command 130 and command 132 are both confirmed. However, in the event that e.g., the message rendered by confirmation process 52 is incorrect (e.g., “Dispense 1.50 U Dose?”), the conversion 152 of command 130 to command 132 has failed. Accordingly, primary microprocessor 114 (and/or the applications being executed on primary microprocessor 114) and/or safety microprocessor 118 (and/or the applications being executed on safety microprocessor 118) may be malfunctioning. Accordingly, user 14 may need to seek an alterative means to having their therapy performed and/or have infusion pump assembly 10 serviced. Accordingly, the operational safety and reliability of infusion pump assembly 10 may be enhanced as any command received is confirmed as being correct by both primary microprocessor 114, safety microprocessor 118, and user 14.
A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made. Accordingly, other implementations are within the scope of the following claims.
Number | Name | Date | Kind |
---|---|---|---|
3631847 | Hobbs, II | Jan 1972 | A |
3692027 | Ellinwood, Jr. | Sep 1972 | A |
3752510 | Windischman et al. | Aug 1973 | A |
3811121 | Heim et al. | May 1974 | A |
3811122 | Raber et al. | May 1974 | A |
3837339 | Aisenberg et al. | Sep 1974 | A |
3887393 | La Rue, Jr. | Jun 1975 | A |
3951147 | Tucker et al. | Apr 1976 | A |
D248873 | Raitto | Aug 1978 | S |
4123631 | Lewis | Oct 1978 | A |
4146029 | Ellinwood, Jr. | Mar 1979 | A |
4150672 | Whitney et al. | Apr 1979 | A |
D254446 | Raitto | Mar 1980 | S |
4206274 | Peels | Jun 1980 | A |
4215701 | Raitto | Aug 1980 | A |
4267836 | Whitney et al. | May 1981 | A |
4269908 | Stemme | May 1981 | A |
4270532 | Franetzki et al. | Jun 1981 | A |
4273121 | Jassawalla | Jun 1981 | A |
4282872 | Franetzki et al. | Aug 1981 | A |
4296949 | Muetterties et al. | Oct 1981 | A |
4331262 | Snyder et al. | May 1982 | A |
4371594 | Ohara et al. | Feb 1983 | A |
4373527 | Fischell | Feb 1983 | A |
4391883 | Williamson et al. | Jul 1983 | A |
4392847 | Whitney et al. | Jul 1983 | A |
4392849 | Petre et al. | Jul 1983 | A |
4395259 | Prestele et al. | Jul 1983 | A |
4437859 | Whitehouse et al. | Mar 1984 | A |
4443218 | DeCant, Jr. et al. | Apr 1984 | A |
4464170 | Clemens et al. | Aug 1984 | A |
4469481 | Kobayashi | Sep 1984 | A |
4475901 | Kraegen et al. | Oct 1984 | A |
4493704 | Beard et al. | Jan 1985 | A |
4494950 | Fischell | Jan 1985 | A |
4498843 | Schneider et al. | Feb 1985 | A |
4533346 | Cosgrove, Jr. et al. | Aug 1985 | A |
4542532 | McQuilkin | Sep 1985 | A |
4543093 | Christinger | Sep 1985 | A |
4550731 | Batina et al. | Nov 1985 | A |
4559037 | Franetzki et al. | Dec 1985 | A |
4559038 | Berg et al. | Dec 1985 | A |
4562751 | Nason et al. | Jan 1986 | A |
4596575 | Rosenberg et al. | Jun 1986 | A |
4624661 | Arimond | Nov 1986 | A |
4633878 | Bombardieri | Jan 1987 | A |
4648872 | Kamen | Mar 1987 | A |
4673396 | Urbaniak | Jun 1987 | A |
4678408 | Nason et al. | Jul 1987 | A |
4685903 | Cable et al. | Aug 1987 | A |
4690878 | Nakamura | Sep 1987 | A |
4696671 | Epstein et al. | Sep 1987 | A |
4731051 | Fischell | Mar 1988 | A |
4731726 | Allen, III | Mar 1988 | A |
4735441 | Stephens | Apr 1988 | A |
4741731 | Starck et al. | May 1988 | A |
4743895 | Alexander | May 1988 | A |
4747828 | Tseo | May 1988 | A |
4790028 | Ramage | Dec 1988 | A |
4803625 | Fu et al. | Feb 1989 | A |
4804368 | Skakoon et al. | Feb 1989 | A |
4809697 | Causey, III et al. | Mar 1989 | A |
4826810 | Aoki | May 1989 | A |
4834712 | Quinn et al. | May 1989 | A |
4849852 | Mullins | Jul 1989 | A |
4856340 | Garrison | Aug 1989 | A |
4871351 | Feingold | Oct 1989 | A |
4880712 | Gordecki | Nov 1989 | A |
4881063 | Fawcett | Nov 1989 | A |
4898578 | Rubalcaba, Jr. | Feb 1990 | A |
4919650 | Feingold et al. | Apr 1990 | A |
4959640 | Hall | Sep 1990 | A |
4972508 | King | Nov 1990 | A |
4988337 | Ito | Jan 1991 | A |
4997423 | Okuda et al. | Mar 1991 | A |
5009646 | Sudo et al. | Apr 1991 | A |
5019974 | Beckers | May 1991 | A |
5034004 | Crankshaw | Jul 1991 | A |
5049141 | Olive | Sep 1991 | A |
5050612 | Matsumura | Sep 1991 | A |
5055830 | Cousins et al. | Oct 1991 | A |
5063291 | Buehring | Nov 1991 | A |
5078683 | Sancoff et al. | Jan 1992 | A |
5080653 | Voss et al. | Jan 1992 | A |
5088981 | Howson et al. | Feb 1992 | A |
5101814 | Palti | Apr 1992 | A |
5102388 | Richmond | Apr 1992 | A |
5103216 | Sisselman | Apr 1992 | A |
5104374 | Bishko et al. | Apr 1992 | A |
5150314 | Garratt et al. | Sep 1992 | A |
5153827 | Coutré et al. | Oct 1992 | A |
5165407 | Wilson et al. | Nov 1992 | A |
5174716 | Hora et al. | Dec 1992 | A |
5176502 | Sanderson et al. | Jan 1993 | A |
5176644 | Srisathapat et al. | Jan 1993 | A |
5176662 | Bartholomew et al. | Jan 1993 | A |
5181910 | Scanlon | Jan 1993 | A |
5187746 | Narisawa | Feb 1993 | A |
5191855 | Conforti | Mar 1993 | A |
5197322 | Indravudh | Mar 1993 | A |
5197895 | Stupecky | Mar 1993 | A |
5205819 | Ross et al. | Apr 1993 | A |
5216597 | Beckers | Jun 1993 | A |
5217442 | Davis | Jun 1993 | A |
5248569 | Pine et al. | Sep 1993 | A |
5254093 | Bartlett et al. | Oct 1993 | A |
5254096 | Rondelet et al. | Oct 1993 | A |
5257971 | Lord et al. | Nov 1993 | A |
5257980 | Van Antwerp et al. | Nov 1993 | A |
5270702 | Krolak | Dec 1993 | A |
5290639 | Mallory | Mar 1994 | A |
5304152 | Sams | Apr 1994 | A |
5307263 | Brown | Apr 1994 | A |
5314416 | Lewis et al. | May 1994 | A |
5317506 | Coutré et al. | May 1994 | A |
5337215 | Sunderland et al. | Aug 1994 | A |
5338157 | Blomquist | Aug 1994 | A |
5339821 | Fujimoto | Aug 1994 | A |
5341291 | Roizen et al. | Aug 1994 | A |
5342324 | Tucker | Aug 1994 | A |
5349852 | Kamen et al. | Sep 1994 | A |
5350411 | Ryan et al. | Sep 1994 | A |
5357427 | Langen et al. | Oct 1994 | A |
5364242 | Olsen | Nov 1994 | A |
5364346 | Schrezenmeir | Nov 1994 | A |
5368562 | Blomquist et al. | Nov 1994 | A |
5370622 | Livingston et al. | Dec 1994 | A |
5372133 | Hogen Esch | Dec 1994 | A |
5376070 | Purvis et al. | Dec 1994 | A |
5383865 | Michel | Jan 1995 | A |
5389078 | Zalesky et al. | Feb 1995 | A |
5390671 | Lord et al. | Feb 1995 | A |
5391157 | Harris et al. | Feb 1995 | A |
5399823 | McCusker | Mar 1995 | A |
5403648 | Chan et al. | Apr 1995 | A |
5417667 | Tennican et al. | May 1995 | A |
5429602 | Hauser | Jul 1995 | A |
5433710 | VanAntwerp et al. | Jul 1995 | A |
5456940 | Funderburk | Oct 1995 | A |
5460618 | Harreld | Oct 1995 | A |
5462525 | Srisathapat et al. | Oct 1995 | A |
5464392 | Epstein et al. | Nov 1995 | A |
5466218 | Srisathapat et al. | Nov 1995 | A |
5472317 | Field et al. | Dec 1995 | A |
5476460 | Montalvo | Dec 1995 | A |
5478211 | Dominiak et al. | Dec 1995 | A |
5482446 | Williamson et al. | Jan 1996 | A |
5497772 | Schulman et al. | Mar 1996 | A |
5505709 | Funderburk et al. | Apr 1996 | A |
5507727 | Crainich | Apr 1996 | A |
5508690 | Shur et al. | Apr 1996 | A |
5514097 | Knauer | May 1996 | A |
5514103 | Srisathapat et al. | May 1996 | A |
5522803 | Teissen-Simony | Jun 1996 | A |
5526844 | Kamen et al. | Jun 1996 | A |
5527307 | Srisathapat et al. | Jun 1996 | A |
5528359 | Taguchi | Jun 1996 | A |
5531697 | Olsen et al. | Jul 1996 | A |
5531698 | Olsen | Jul 1996 | A |
5533389 | Kamen et al. | Jul 1996 | A |
5533996 | Murphey et al. | Jul 1996 | A |
5538399 | Johnson | Jul 1996 | A |
5540564 | Klopfer | Jul 1996 | A |
5543588 | Bisset et al. | Aug 1996 | A |
5545140 | Conero et al. | Aug 1996 | A |
5545142 | Stephens et al. | Aug 1996 | A |
5545143 | Fischell | Aug 1996 | A |
5545152 | Funderburk et al. | Aug 1996 | A |
5558640 | Pfeiler et al. | Sep 1996 | A |
5558641 | Glantz et al. | Sep 1996 | A |
5562618 | Cai et al. | Oct 1996 | A |
5564915 | Johnson | Oct 1996 | A |
5567119 | Johnson | Oct 1996 | A |
5567136 | Johnson | Oct 1996 | A |
5569026 | Novak | Oct 1996 | A |
5569186 | Lord et al. | Oct 1996 | A |
5569187 | Kaiser | Oct 1996 | A |
5573506 | Vasko | Nov 1996 | A |
5575310 | Kamen et al. | Nov 1996 | A |
5582593 | Hultman | Dec 1996 | A |
5584813 | Livingston et al. | Dec 1996 | A |
5593390 | Castellano et al. | Jan 1997 | A |
5594638 | Iliff | Jan 1997 | A |
5609060 | Dent | Mar 1997 | A |
5609575 | Larson et al. | Mar 1997 | A |
5613945 | Cai et al. | Mar 1997 | A |
5620312 | Hyman et al. | Apr 1997 | A |
5626144 | Tacklind et al. | May 1997 | A |
5630710 | Tune et al. | May 1997 | A |
5632729 | Cai et al. | May 1997 | A |
5637095 | Nason et al. | Jun 1997 | A |
5637420 | Jones, Jr. et al. | Jun 1997 | A |
5641892 | Larkins et al. | Jun 1997 | A |
5643212 | Coutré et al. | Jul 1997 | A |
5647853 | Feldmann et al. | Jul 1997 | A |
5647854 | Olsen et al. | Jul 1997 | A |
5651775 | Walker et al. | Jul 1997 | A |
5658133 | Anderson et al. | Aug 1997 | A |
5658250 | Blomquist et al. | Aug 1997 | A |
5658252 | Johnson | Aug 1997 | A |
5660176 | Iliff | Aug 1997 | A |
5665065 | Colman et al. | Sep 1997 | A |
5669877 | Blomquist | Sep 1997 | A |
5669887 | Cooper | Sep 1997 | A |
5678568 | Uchikubo et al. | Oct 1997 | A |
5681285 | Ford et al. | Oct 1997 | A |
5685844 | Marttila | Nov 1997 | A |
5687734 | Dempsey et al. | Nov 1997 | A |
5695473 | Olsen | Dec 1997 | A |
5704366 | Tacklind et al. | Jan 1998 | A |
5713856 | Eggers et al. | Feb 1998 | A |
5713857 | Grimard et al. | Feb 1998 | A |
5716725 | Riveron et al. | Feb 1998 | A |
5718562 | Lawless et al. | Feb 1998 | A |
5720729 | Kriesel | Feb 1998 | A |
5727241 | Yamano et al. | Mar 1998 | A |
5733673 | Kunert | Mar 1998 | A |
5743873 | Cai et al. | Apr 1998 | A |
5752940 | Grimard | May 1998 | A |
5755744 | Shaw et al. | May 1998 | A |
5762632 | Whisson | Jun 1998 | A |
5764159 | Neftel | Jun 1998 | A |
5772409 | Johnson | Jun 1998 | A |
5772635 | Dastur et al. | Jun 1998 | A |
5776116 | Lopez et al. | Jul 1998 | A |
5779665 | Mastrototaro et al. | Jul 1998 | A |
5785681 | Indravudh | Jul 1998 | A |
5788669 | Peterson | Aug 1998 | A |
5788671 | Johnson | Aug 1998 | A |
5788673 | Young et al. | Aug 1998 | A |
5788678 | Van Antwerp | Aug 1998 | A |
5795337 | Grimard | Aug 1998 | A |
5800387 | Duffy et al. | Sep 1998 | A |
5800420 | Gross et al. | Sep 1998 | A |
5801600 | Butland et al. | Sep 1998 | A |
5807336 | Russo et al. | Sep 1998 | A |
5810001 | Genga et al. | Sep 1998 | A |
5810771 | Blomquist | Sep 1998 | A |
5814015 | Gargano et al. | Sep 1998 | A |
5822715 | Worthington et al. | Oct 1998 | A |
5823746 | Johnson | Oct 1998 | A |
5832448 | Brown | Nov 1998 | A |
5840020 | Heinonen et al. | Nov 1998 | A |
5840026 | Uber, III et al. | Nov 1998 | A |
5843146 | Cross, Jr. | Dec 1998 | A |
5851197 | Marano et al. | Dec 1998 | A |
5851692 | Potts | Dec 1998 | A |
5861018 | Feierbach | Jan 1999 | A |
5868669 | Iliff | Feb 1999 | A |
5871465 | Vasko | Feb 1999 | A |
5876370 | Blomquist | Mar 1999 | A |
5879143 | Cote et al. | Mar 1999 | A |
5879144 | Johnson | Mar 1999 | A |
5879163 | Brown et al. | Mar 1999 | A |
5882256 | Shropshire | Mar 1999 | A |
5885245 | Lynch et al. | Mar 1999 | A |
5897493 | Brown | Apr 1999 | A |
5899855 | Brown | May 1999 | A |
5913310 | Brown | Jun 1999 | A |
5918603 | Brown | Jul 1999 | A |
5925021 | Castellano et al. | Jul 1999 | A |
5928196 | Johnson et al. | Jul 1999 | A |
5928202 | Linnebjerg | Jul 1999 | A |
5931791 | Saltzstein et al. | Aug 1999 | A |
5933136 | Brown | Aug 1999 | A |
5935099 | Peterson et al. | Aug 1999 | A |
5935105 | Manning et al. | Aug 1999 | A |
5935106 | Olsen | Aug 1999 | A |
5940801 | Brown | Aug 1999 | A |
5951521 | Mastrototaro et al. | Sep 1999 | A |
5954485 | Johnson et al. | Sep 1999 | A |
5954697 | Srisathapat et al. | Sep 1999 | A |
5954700 | Kovelman | Sep 1999 | A |
5956501 | Brown | Sep 1999 | A |
5957890 | Mann et al. | Sep 1999 | A |
5960403 | Brown | Sep 1999 | A |
5968011 | Larsen et al. | Oct 1999 | A |
5971963 | Choi | Oct 1999 | A |
5973623 | Gupta et al. | Oct 1999 | A |
5980506 | Mathiasen | Nov 1999 | A |
5989216 | Johnson et al. | Nov 1999 | A |
5989227 | Vetter et al. | Nov 1999 | A |
5997476 | Brown | Dec 1999 | A |
6007941 | Hermann et al. | Dec 1999 | A |
6009339 | Bentsen et al. | Dec 1999 | A |
6014587 | Shaw et al. | Jan 2000 | A |
6017326 | Pasqualucci et al. | Jan 2000 | A |
6017328 | Fischell et al. | Jan 2000 | A |
6024539 | Blomquist | Feb 2000 | A |
6032119 | Brown et al. | Feb 2000 | A |
6042565 | Hirschman et al. | Mar 2000 | A |
6056522 | Johnson | May 2000 | A |
6056718 | Funderburk et al. | May 2000 | A |
6059753 | Faust et al. | May 2000 | A |
6063059 | Kriesel | May 2000 | A |
6073036 | Heikkinen et al. | Jun 2000 | A |
6077055 | Vilks | Jun 2000 | A |
6086575 | Mejslov | Jul 2000 | A |
6090081 | Sudo et al. | Jul 2000 | A |
6093172 | Funderburk et al. | Jul 2000 | A |
6096011 | Trombley, III et al. | Aug 2000 | A |
6099507 | Heinzerling | Aug 2000 | A |
6101478 | Brown | Aug 2000 | A |
6110152 | Kovelman | Aug 2000 | A |
6112111 | Glantz | Aug 2000 | A |
6123686 | Olsen et al. | Sep 2000 | A |
6123690 | Mejslov | Sep 2000 | A |
6135949 | Russo et al. | Oct 2000 | A |
6165154 | Gray et al. | Dec 2000 | A |
6171287 | Lynn et al. | Jan 2001 | B1 |
6202708 | Bynum | Mar 2001 | B1 |
6206856 | Mahurkar | Mar 2001 | B1 |
6211856 | Choi et al. | Apr 2001 | B1 |
6216795 | Buchl | Apr 2001 | B1 |
6225711 | Gupta et al. | May 2001 | B1 |
6241704 | Peterson et al. | Jun 2001 | B1 |
6246992 | Brown | Jun 2001 | B1 |
6248093 | Moberg | Jun 2001 | B1 |
6253804 | Safabash | Jul 2001 | B1 |
6254586 | Mann et al. | Jul 2001 | B1 |
6259587 | Sheldon et al. | Jul 2001 | B1 |
6267564 | Rapheal | Jul 2001 | B1 |
6269340 | Ford et al. | Jul 2001 | B1 |
6270455 | Brown | Aug 2001 | B1 |
6280416 | Van Antwerp et al. | Aug 2001 | B1 |
6283943 | Dy et al. | Sep 2001 | B1 |
6293159 | Kriesel et al. | Sep 2001 | B1 |
6293925 | Safabash et al. | Sep 2001 | B1 |
6305908 | Hermann et al. | Oct 2001 | B1 |
6309375 | Glines et al. | Oct 2001 | B1 |
6311868 | Krietemeier et al. | Nov 2001 | B1 |
6321158 | DeLorme et al. | Nov 2001 | B1 |
6362591 | Moberg | Mar 2002 | B1 |
6364859 | St. Romain et al. | Apr 2002 | B1 |
6364865 | Lavi et al. | Apr 2002 | B1 |
6374876 | Bynum | Apr 2002 | B2 |
6375638 | Nason et al. | Apr 2002 | B2 |
6416293 | Bouchard et al. | Jul 2002 | B1 |
6422057 | Anderson | Jul 2002 | B1 |
6423035 | Das et al. | Jul 2002 | B1 |
6427088 | Bowman, IV et al. | Jul 2002 | B1 |
6428509 | Fielder | Aug 2002 | B1 |
6447481 | Duchon et al. | Sep 2002 | B1 |
6453956 | Safabash | Sep 2002 | B2 |
6458102 | Mann et al. | Oct 2002 | B1 |
6459424 | Resman | Oct 2002 | B1 |
6461329 | Van Antwerp et al. | Oct 2002 | B1 |
6461331 | Van Antwerp | Oct 2002 | B1 |
6466203 | Van Ee | Oct 2002 | B2 |
6475180 | Peterson et al. | Nov 2002 | B2 |
6475196 | Vachon | Nov 2002 | B1 |
6485461 | Mason et al. | Nov 2002 | B1 |
6485465 | Moberg et al. | Nov 2002 | B2 |
6520938 | Funderburk et al. | Feb 2003 | B1 |
6537268 | Gibson et al. | Mar 2003 | B1 |
6549423 | Brodnick | Apr 2003 | B1 |
6551276 | Mann et al. | Apr 2003 | B1 |
6551277 | Ford | Apr 2003 | B1 |
6554798 | Mann et al. | Apr 2003 | B1 |
6554800 | Nezhadian et al. | Apr 2003 | B1 |
6555986 | Moberg | Apr 2003 | B2 |
6558320 | Causey, III et al. | May 2003 | B1 |
6558351 | Steil et al. | May 2003 | B1 |
6562001 | Lebel et al. | May 2003 | B2 |
6562023 | Marrs et al. | May 2003 | B1 |
6564105 | Starkweather et al. | May 2003 | B2 |
6571128 | Lebel et al. | May 2003 | B2 |
6572542 | Houben et al. | Jun 2003 | B1 |
6572586 | Wojcik | Jun 2003 | B1 |
6577899 | Lebel et al. | Jun 2003 | B2 |
RE38189 | Walker et al. | Jul 2003 | E |
6585644 | Lebel et al. | Jul 2003 | B2 |
6585695 | Adair et al. | Jul 2003 | B1 |
6591876 | Safabash | Jul 2003 | B2 |
6592551 | Cobb | Jul 2003 | B1 |
6595756 | Gray et al. | Jul 2003 | B2 |
6607509 | Bobroff et al. | Aug 2003 | B2 |
6613015 | Sandstrom et al. | Sep 2003 | B2 |
D480477 | Bush et al. | Oct 2003 | S |
6641533 | Causey, III et al. | Nov 2003 | B2 |
6642936 | Engholm et al. | Nov 2003 | B1 |
6645177 | Shearn | Nov 2003 | B1 |
6648821 | Lebel et al. | Nov 2003 | B2 |
6652493 | Das | Nov 2003 | B1 |
6652510 | Lord et al. | Nov 2003 | B2 |
6656148 | Das et al. | Dec 2003 | B2 |
6656158 | Mahoney et al. | Dec 2003 | B2 |
6656159 | Flaherty | Dec 2003 | B2 |
6659948 | Lebel et al. | Dec 2003 | B2 |
6665909 | Collins et al. | Dec 2003 | B2 |
6669669 | Flaherty et al. | Dec 2003 | B2 |
6684058 | Karacaoglu et al. | Jan 2004 | B1 |
6685678 | Evans et al. | Feb 2004 | B2 |
6687546 | Lebel et al. | Feb 2004 | B2 |
6689091 | Bui et al. | Feb 2004 | B2 |
6691043 | Ribeiro, Jr. | Feb 2004 | B2 |
6692457 | Flaherty | Feb 2004 | B2 |
6694191 | Starkweather et al. | Feb 2004 | B2 |
6699218 | Flaherty et al. | Mar 2004 | B2 |
6704034 | Rodriguez et al. | Mar 2004 | B1 |
6716195 | Nolan, Jr. et al. | Apr 2004 | B2 |
6723072 | Flaherty et al. | Apr 2004 | B2 |
6733446 | Lebel et al. | May 2004 | B2 |
6740059 | Flaherty | May 2004 | B2 |
6740072 | Starkweather et al. | May 2004 | B2 |
6740075 | Lebel et al. | May 2004 | B2 |
6743205 | Nolan, Jr. et al. | Jun 2004 | B2 |
6744350 | Blomquist | Jun 2004 | B2 |
6749586 | Vasko | Jun 2004 | B2 |
6749587 | Flaherty | Jun 2004 | B2 |
6752299 | Shetler et al. | Jun 2004 | B2 |
6752785 | Van Antwerp et al. | Jun 2004 | B2 |
6752787 | Causey, III et al. | Jun 2004 | B1 |
6758810 | Lebel et al. | Jul 2004 | B2 |
6768425 | Flaherty et al. | Jul 2004 | B2 |
6770067 | Lorenzen et al. | Aug 2004 | B2 |
6772650 | Ohyama et al. | Aug 2004 | B2 |
6800071 | McConnell et al. | Oct 2004 | B1 |
6801420 | Talbot et al. | Oct 2004 | B2 |
6805693 | Gray et al. | Oct 2004 | B2 |
6810290 | Lebel et al. | Oct 2004 | B2 |
6811533 | Lebel et al. | Nov 2004 | B2 |
6811534 | Bowman, IV et al. | Nov 2004 | B2 |
6813519 | Lebel et al. | Nov 2004 | B2 |
6817990 | Yap et al. | Nov 2004 | B2 |
6827702 | Lebel et al. | Dec 2004 | B2 |
6830558 | Flaherty et al. | Dec 2004 | B2 |
6835190 | Nguyen | Dec 2004 | B2 |
6845465 | Hashemi | Jan 2005 | B2 |
6852104 | Blomquist | Feb 2005 | B2 |
6854620 | Ramey | Feb 2005 | B2 |
6872200 | Mann et al. | Mar 2005 | B2 |
6873268 | Lebel et al. | Mar 2005 | B2 |
6879930 | Sinclair et al. | Apr 2005 | B2 |
6902207 | Lickliter | Jun 2005 | B2 |
6916010 | Beck et al. | Jul 2005 | B2 |
6930602 | Villaseca et al. | Aug 2005 | B2 |
6932584 | Gray et al. | Aug 2005 | B2 |
6936029 | Mann et al. | Aug 2005 | B2 |
6945760 | Gray et al. | Sep 2005 | B2 |
6950708 | Bowman, IV et al. | Sep 2005 | B2 |
6951551 | Hudon | Oct 2005 | B2 |
6958705 | Lebel et al. | Oct 2005 | B2 |
6960192 | Flaherty et al. | Nov 2005 | B1 |
6960195 | Heinz et al. | Nov 2005 | B2 |
6964643 | Hovland et al. | Nov 2005 | B2 |
6974437 | Lebel et al. | Dec 2005 | B2 |
6978517 | Collins et al. | Dec 2005 | B2 |
6979326 | Mann et al. | Dec 2005 | B2 |
6994619 | Scholten | Feb 2006 | B2 |
6997905 | Gillespie, Jr. et al. | Feb 2006 | B2 |
6997907 | Safabash et al. | Feb 2006 | B2 |
6997910 | Howlett et al. | Feb 2006 | B2 |
6997920 | Mann et al. | Feb 2006 | B2 |
6997921 | Gray et al. | Feb 2006 | B2 |
6999854 | Roth | Feb 2006 | B2 |
7011608 | Spencer | Mar 2006 | B2 |
7018360 | Flaherty et al. | Mar 2006 | B2 |
7021560 | Gray et al. | Apr 2006 | B2 |
7024245 | Lebel et al. | Apr 2006 | B2 |
7025226 | Ramey | Apr 2006 | B2 |
7025743 | Mann et al. | Apr 2006 | B2 |
7029455 | Flaherty | Apr 2006 | B2 |
7029456 | Ware et al. | Apr 2006 | B2 |
7033338 | Vilks et al. | Apr 2006 | B2 |
7033339 | Lynn | Apr 2006 | B1 |
7041082 | Blomquist et al. | May 2006 | B2 |
7045361 | Heiss et al. | May 2006 | B2 |
7046230 | Zadesky et al. | May 2006 | B2 |
7050927 | Sinclair et al. | May 2006 | B2 |
7052251 | Nason et al. | May 2006 | B2 |
7052483 | Wojcik | May 2006 | B2 |
7061140 | Zhang et al. | Jun 2006 | B2 |
7063684 | Moberg | Jun 2006 | B2 |
7066029 | Beavis et al. | Jun 2006 | B2 |
7074209 | Evans et al. | Jul 2006 | B2 |
7075512 | Fabre et al. | Jul 2006 | B1 |
7098803 | Mann et al. | Aug 2006 | B2 |
7109878 | Mann et al. | Sep 2006 | B2 |
7115113 | Evans et al. | Oct 2006 | B2 |
7131967 | Gray et al. | Nov 2006 | B2 |
7137964 | Flaherty | Nov 2006 | B2 |
7144384 | Gorman et al. | Dec 2006 | B2 |
7146977 | Beavis et al. | Dec 2006 | B2 |
7278983 | Ireland et al. | Oct 2007 | B2 |
7303549 | Flaherty et al. | Dec 2007 | B2 |
7305984 | Altobelli et al. | Dec 2007 | B2 |
7306578 | Gray et al. | Dec 2007 | B2 |
7342660 | Altobelli et al. | Mar 2008 | B2 |
7498563 | Mandro et al. | Mar 2009 | B2 |
7682338 | Griffin | Mar 2010 | B2 |
7927314 | Kuracina et al. | Apr 2011 | B2 |
8016789 | Grant et al. | Sep 2011 | B2 |
20010034502 | Moberg et al. | Oct 2001 | A1 |
20010041869 | Causey, III et al. | Nov 2001 | A1 |
20010056258 | Evans | Dec 2001 | A1 |
20020002326 | Causey, III et al. | Jan 2002 | A1 |
20020013613 | Haller et al. | Jan 2002 | A1 |
20020022807 | Duchon et al. | Feb 2002 | A1 |
20020038392 | De La Huerga | Mar 2002 | A1 |
20020043951 | Moberg | Apr 2002 | A1 |
20020052539 | Haller et al. | May 2002 | A1 |
20020052574 | Hochman et al. | May 2002 | A1 |
20020056114 | Fillebrown et al. | May 2002 | A1 |
20020077852 | Ford et al. | Jun 2002 | A1 |
20020082665 | Haller et al. | Jun 2002 | A1 |
20020091454 | Vasko | Jul 2002 | A1 |
20020107481 | Reilly et al. | Aug 2002 | A1 |
20020123672 | Christophersom et al. | Sep 2002 | A1 |
20020126036 | Flaherty et al. | Sep 2002 | A1 |
20020143290 | Bui et al. | Oct 2002 | A1 |
20020158838 | Smith et al. | Oct 2002 | A1 |
20020169439 | Flaherty | Nov 2002 | A1 |
20020173748 | McConnell et al. | Nov 2002 | A1 |
20020193679 | Malave et al. | Dec 2002 | A1 |
20020193846 | Pool et al. | Dec 2002 | A1 |
20030009133 | Ramey | Jan 2003 | A1 |
20030014013 | Choi | Jan 2003 | A1 |
20030028079 | Lebel et al. | Feb 2003 | A1 |
20030028346 | Sinclair et al. | Feb 2003 | A1 |
20030065308 | Lebel et al. | Apr 2003 | A1 |
20030076306 | Zadesky et al. | Apr 2003 | A1 |
20030088238 | Poulsen et al. | May 2003 | A1 |
20030114836 | Estes et al. | Jun 2003 | A1 |
20030125672 | Adair et al. | Jul 2003 | A1 |
20030130618 | Gray et al. | Jul 2003 | A1 |
20030132922 | Philipp | Jul 2003 | A1 |
20030141981 | Bui et al. | Jul 2003 | A1 |
20030161744 | Vilks et al. | Aug 2003 | A1 |
20030163089 | Bynum | Aug 2003 | A1 |
20030163090 | Blomquist et al. | Aug 2003 | A1 |
20030187525 | Mann et al. | Oct 2003 | A1 |
20030191431 | Mann et al. | Oct 2003 | A1 |
20030195462 | Mann et al. | Oct 2003 | A1 |
20030212364 | Mann et al. | Nov 2003 | A1 |
20030212379 | Bylund et al. | Nov 2003 | A1 |
20030229311 | Morris et al. | Dec 2003 | A1 |
20030233069 | Gillespie, Jr. et al. | Dec 2003 | A1 |
20040003493 | Adair et al. | Jan 2004 | A1 |
20040054326 | Hommann et al. | Mar 2004 | A1 |
20040059315 | Erickson et al. | Mar 2004 | A1 |
20040064088 | Gorman et al. | Apr 2004 | A1 |
20040068230 | Estes et al. | Apr 2004 | A1 |
20040073095 | Causey, III et al. | Apr 2004 | A1 |
20040073161 | Tachibana | Apr 2004 | A1 |
20040082908 | Whitehurst et al. | Apr 2004 | A1 |
20040082918 | Evans et al. | Apr 2004 | A1 |
20040085215 | Moberg et al. | May 2004 | A1 |
20040092873 | Moberg | May 2004 | A1 |
20040116893 | Spohn et al. | Jun 2004 | A1 |
20040121767 | Simpson et al. | Jun 2004 | A1 |
20040127958 | Mazar et al. | Jul 2004 | A1 |
20040133166 | Moberg et al. | Jul 2004 | A1 |
20040135078 | Mandro et al. | Jul 2004 | A1 |
20040140304 | Leyendecker | Jul 2004 | A1 |
20040158193 | Bui et al. | Aug 2004 | A1 |
20040162528 | Horvath et al. | Aug 2004 | A1 |
20040167464 | Ireland et al. | Aug 2004 | A1 |
20040172301 | Mihai et al. | Sep 2004 | A1 |
20040176667 | Mihai et al. | Sep 2004 | A1 |
20040176725 | Stutz et al. | Sep 2004 | A1 |
20040193090 | Lebel et al. | Sep 2004 | A1 |
20040207404 | Zhang et al. | Oct 2004 | A1 |
20040235446 | Flaherty et al. | Nov 2004 | A1 |
20040243065 | McConnell et al. | Dec 2004 | A1 |
20050015056 | Duchon et al. | Jan 2005 | A1 |
20050021000 | Adair et al. | Jan 2005 | A1 |
20050022274 | Campbell et al. | Jan 2005 | A1 |
20050027254 | Vasko | Feb 2005 | A1 |
20050035956 | Sinclair et al. | Feb 2005 | A1 |
20050048900 | Scholten | Mar 2005 | A1 |
20050052429 | Philipp | Mar 2005 | A1 |
20050055242 | Bello et al. | Mar 2005 | A1 |
20050055244 | Mullan et al. | Mar 2005 | A1 |
20050062732 | Sinclair et al. | Mar 2005 | A1 |
20050063857 | Alheidt et al. | Mar 2005 | A1 |
20050065464 | Talbot et al. | Mar 2005 | A1 |
20050065817 | Mihai et al. | Mar 2005 | A1 |
20050069425 | Gray et al. | Mar 2005 | A1 |
20050085760 | Ware et al. | Apr 2005 | A1 |
20050096593 | Pope et al. | May 2005 | A1 |
20050137530 | Campbell et al. | Jun 2005 | A1 |
20050137573 | McLaughlin | Jun 2005 | A1 |
20050148938 | Blomquist | Jul 2005 | A1 |
20050171512 | Flaherty | Aug 2005 | A1 |
20050171513 | Mann et al. | Aug 2005 | A1 |
20050177111 | Ozeri et al. | Aug 2005 | A1 |
20050182366 | Vogt et al. | Aug 2005 | A1 |
20050182389 | LaPorte et al. | Aug 2005 | A1 |
20050187515 | Varrichio et al. | Aug 2005 | A1 |
20050187593 | Housworth et al. | Aug 2005 | A1 |
20050192494 | Ginsberg | Sep 2005 | A1 |
20050203461 | Flaherty et al. | Sep 2005 | A1 |
20050215982 | Malave et al. | Sep 2005 | A1 |
20050224705 | Tobiason et al. | Oct 2005 | A1 |
20050234404 | Vilks et al. | Oct 2005 | A1 |
20050238503 | Rush et al. | Oct 2005 | A1 |
20050238507 | DiIanni et al. | Oct 2005 | A1 |
20050245904 | Estes et al. | Nov 2005 | A1 |
20050250368 | Singer et al. | Nov 2005 | A1 |
20050261660 | Choi | Nov 2005 | A1 |
20050263615 | Kriesel et al. | Dec 2005 | A1 |
20050267363 | Duchon et al. | Dec 2005 | A1 |
20050267550 | Hess et al. | Dec 2005 | A1 |
20050267928 | Anderson et al. | Dec 2005 | A1 |
20050273059 | Mernoe et al. | Dec 2005 | A1 |
20050285880 | Lai et al. | Dec 2005 | A1 |
20060016800 | Paradiso et al. | Jan 2006 | A1 |
20060025663 | Talbot et al. | Feb 2006 | A1 |
20060026535 | Hotelling et al. | Feb 2006 | A1 |
20060026536 | Hotelling et al. | Feb 2006 | A1 |
20060038791 | Mackey | Feb 2006 | A1 |
20060041229 | Garibotto et al. | Feb 2006 | A1 |
20060065772 | Grant et al. | Mar 2006 | A1 |
20060066581 | Lyon et al. | Mar 2006 | A1 |
20060097991 | Hotelling et al. | May 2006 | A1 |
20060100591 | Alheidt et al. | May 2006 | A1 |
20060106346 | Sullivan et al. | May 2006 | A1 |
20060123884 | Selker et al. | Jun 2006 | A1 |
20060129112 | Lynn | Jun 2006 | A1 |
20060144942 | Evans et al. | Jul 2006 | A1 |
20060160670 | Spencer | Jul 2006 | A1 |
20060161870 | Hotelling et al. | Jul 2006 | A1 |
20060161871 | Hotelling et al. | Jul 2006 | A1 |
20060173406 | Hayes et al. | Aug 2006 | A1 |
20060173444 | Choy et al. | Aug 2006 | A1 |
20060178633 | Garibotto et al. | Aug 2006 | A1 |
20060178836 | Bai et al. | Aug 2006 | A1 |
20060184084 | Ware et al. | Aug 2006 | A1 |
20060184123 | Gillespie, Jr. et al. | Aug 2006 | A1 |
20060184154 | Moberg et al. | Aug 2006 | A1 |
20060200257 | Kirste et al. | Sep 2006 | A1 |
20060227117 | Proctor | Oct 2006 | A1 |
20060229557 | Fathallah et al. | Oct 2006 | A1 |
20060232554 | Wong et al. | Oct 2006 | A1 |
20060236262 | Bathiche et al. | Oct 2006 | A1 |
20060236263 | Bathiche et al. | Oct 2006 | A1 |
20060253085 | Geismar et al. | Nov 2006 | A1 |
20060264894 | Moberg et al. | Nov 2006 | A1 |
20060282290 | Flaherty et al. | Dec 2006 | A1 |
20070049870 | Gray et al. | Mar 2007 | A1 |
20070060872 | Hall et al. | Mar 2007 | A1 |
20070066956 | Finkel | Mar 2007 | A1 |
20070093750 | Jan et al. | Apr 2007 | A1 |
20070112298 | Mueller, Jr. et al. | May 2007 | A1 |
20070118405 | Campbell et al. | May 2007 | A1 |
20070161955 | Bynum et al. | Jul 2007 | A1 |
20070167905 | Estes et al. | Jul 2007 | A1 |
20070178776 | Etter et al. | Aug 2007 | A1 |
20070191770 | Moberg et al. | Aug 2007 | A1 |
20070219480 | Kamen et al. | Sep 2007 | A1 |
20070219496 | Kamen et al. | Sep 2007 | A1 |
20070219597 | Kamen et al. | Sep 2007 | A1 |
20070228071 | Kamen et al. | Oct 2007 | A1 |
20070255250 | Moberg et al. | Nov 2007 | A1 |
20070258395 | Jollota et al. | Nov 2007 | A1 |
20080009824 | Moberg et al. | Jan 2008 | A1 |
20080051710 | Moberg et al. | Feb 2008 | A1 |
20080051711 | Mounce et al. | Feb 2008 | A1 |
20080097321 | Mounce et al. | Apr 2008 | A1 |
20080097328 | Moberg et al. | Apr 2008 | A1 |
20080125701 | Moberg et al. | May 2008 | A1 |
20080160492 | Campbell et al. | Jul 2008 | A1 |
20080161754 | Marano-Ford | Jul 2008 | A1 |
20080177900 | Grant et al. | Jul 2008 | A1 |
20090036870 | Mounce et al. | Feb 2009 | A1 |
20090062767 | Van Antwerp et al. | Mar 2009 | A1 |
20090062778 | Bengtsson et al. | Mar 2009 | A1 |
20090069749 | Miller et al. | Mar 2009 | A1 |
20090099523 | Grant et al. | Apr 2009 | A1 |
20090164251 | Hayter | Jun 2009 | A1 |
20090171291 | Bente, IV et al. | Jul 2009 | A1 |
20090234213 | Hayes et al. | Sep 2009 | A1 |
20090259217 | Hyde et al. | Oct 2009 | A1 |
20090270811 | Mounce et al. | Oct 2009 | A1 |
20100063445 | Sternberg et al. | Mar 2010 | A1 |
Number | Date | Country |
---|---|---|
4329229 | Mar 1995 | DE |
19627619 | Jan 1998 | DE |
20110059 | Aug 2002 | DE |
0256694 | Feb 1988 | EP |
0258566 | Mar 1988 | EP |
0338671 | Oct 1989 | EP |
0398394 | Nov 1990 | EP |
0554995 | Aug 1993 | EP |
0749757 | Dec 1996 | EP |
0763368 | Mar 1997 | EP |
0806738 | Nov 1997 | EP |
0830597 | Mar 1998 | EP |
0917882 | May 1999 | EP |
1109586 | Jun 2001 | EP |
1177802 | Feb 2002 | EP |
1338295 | Aug 2003 | EP |
1473050 | Mar 2004 | EP |
1115435 | Aug 2005 | EP |
1347705 | Dec 2005 | EP |
1 007 137 | Apr 2006 | EP |
1688085 | Aug 2006 | EP |
1839694 | Oct 2007 | EP |
2218831 | Nov 1989 | GB |
9408647 | Apr 1994 | WO |
9524229 | Sep 1995 | WO |
9528878 | Nov 1995 | WO |
9531233 | Nov 1995 | WO |
9608281 | Mar 1996 | WO |
9614100 | May 1996 | WO |
9620745 | Jul 1996 | WO |
9636389 | Nov 1996 | WO |
9721456 | Jun 1997 | WO |
9740482 | Oct 1997 | WO |
9817336 | Apr 1998 | WO |
9820439 | May 1998 | WO |
9824358 | Jun 1998 | WO |
WO 9814234 | Sep 1998 | WO |
9842407 | Oct 1998 | WO |
9849659 | Nov 1998 | WO |
9858693 | Dec 1998 | WO |
9859487 | Dec 1998 | WO |
9908183 | Feb 1999 | WO |
9910801 | Mar 1999 | WO |
9918532 | Apr 1999 | WO |
9922236 | May 1999 | WO |
9944655 | Sep 1999 | WO |
9959663 | Nov 1999 | WO |
0010628 | Mar 2000 | WO |
0028217 | May 2000 | WO |
0069493 | Nov 2000 | WO |
0100261 | Jan 2001 | WO |
0161616 | Aug 2001 | WO |
0170304 | Sep 2001 | WO |
0204047 | Jan 2002 | WO |
0224257 | Mar 2002 | WO |
0249509 | Jun 2002 | WO |
02053220 | Jul 2002 | WO |
02056945 | Jul 2002 | WO |
02070049 | Sep 2002 | WO |
02083209 | Oct 2002 | WO |
03053498 | Jul 2003 | WO |
03059422 | Jul 2003 | WO |
03063932 | Aug 2003 | WO |
03071930 | Sep 2003 | WO |
03090838 | Nov 2003 | WO |
03094075 | Nov 2003 | WO |
2004007133 | Jan 2004 | WO |
2004008956 | Jan 2004 | WO |
2004009160 | Jan 2004 | WO |
2004006981 | Jan 2004 | WO |
2004-028596 | Apr 2004 | WO |
2004058327 | Jul 2004 | WO |
2004069095 | Aug 2004 | WO |
2004070548 | Aug 2004 | WO |
2004070557 | Aug 2004 | WO |
2004070994 | Aug 2004 | WO |
2004070995 | Aug 2004 | WO |
2004098390 | Nov 2004 | WO |
2005000378 | Jan 2005 | WO |
2005010796 | Feb 2005 | WO |
2005016411 | Feb 2005 | WO |
2005019766 | Mar 2005 | WO |
2005019987 | Mar 2005 | WO |
WO 2005039671 | Jun 2005 | WO |
2005094920 | Oct 2005 | WO |
2005101279 | Oct 2005 | WO |
2005-102416 | Nov 2005 | WO |
2005112899 | Dec 2005 | WO |
2005121938 | Dec 2005 | WO |
2006001929 | Jan 2006 | WO |
2006023147 | Mar 2006 | WO |
2006032652 | Mar 2006 | WO |
2006081975 | Aug 2006 | WO |
2006083831 | Aug 2006 | WO |
2006097453 | Sep 2006 | WO |
2006108809 | Oct 2006 | WO |
2007016145 | Feb 2007 | WO |
Number | Date | Country | |
---|---|---|---|
20100094221 A1 | Apr 2010 | US |